However, another study [12] indicated that expression levels of ANXA2 in HCC tissue and serum specimens were not correlated well with clinical outcomes, suggesting that ANXA2 was not a good prognostic maker for HCC patients with HBV-related liver cirrhosis. This evidence concerns the gene ANXA2 and hepatocellular carcinoma.